Unity Biotechnology, Inc. Common Stock

UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Related tickers: UBX.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. (NASDAQ: UBX) from $10 to $8. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating. Unity Biotechnology shares gained 1.3% to close at $1.52 on Tuesday. See how other analysts view this stock. TD Cowen slashed the price target for Amgen Inc. (NASDAQ: AMGN) from $370 to $360. TD Cowen analyst Yaron Weber maintained the stock with a Buy rating. Amgen shares rose 0.1% to close at $265.64 on Tuesday. See how other analysts view this stock. B of A Securities cut Johnson & Johnson (NYSE: JNJ) price target from $180 to $170. B of A Securities analyst Geoff Meacham maintained a Neutral rating. Johnson & Johnson shares fell 2.1% to close at $144.45 on Tuesday. See how other analysts view this stock. Morgan Stanley raised the price target ...Full story available on Benzinga.com

Related tickers: AMGN, JBHT, STRA, URBN, BK, JNJ, V, AR, MRNS, UBX.